Pieris Pharmaceuticals Announces Presentation of In Vivo

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR)

BOSTON, MA --(Marketwired - March 17, 2016) - Pieris Pharmaceuticals, Inc . ( NASDAQ : PIRS ), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform, announced today that in vivo proof of concept data for anti-tumor activity of PRS-343, the Company's lead bispecific immuno-oncology drug candidate, will be highlighted in a poster session at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) to be held in New Orleans, April 16-20, 2016. PRS-343 binds to CD137 (4-1BB) on T cells and HER2 on tumor cells, producing tumor-targeted immune activation.

In a humanized mouse model engrafted with a HER2-positive human tumor cell-line and human peripheral blood mononuclear cells, treatment with PRS-343 led to tumor growth inhibition superior to that observed with either an isotype control or a benchmark CD137-targeting antibody. The data to be presented, which includes phenotyping of peripheral and intra-tumoral lymphocytes, support the intended mode of action of tumor-localized costimulatory T cell activation with an enhanced therapeutic index compared to anti-CD137 antibody approaches.

Further details include:

Poster Number:  556

Title: Costimulatory T cell engagement by the HER2/CD137 bispecific PRS-343 leads to strong anti-tumor effect in humanized mouse model

Date and Time:  Sunday Apr 17, 2016, 1:00 PM - 5:00 PM

Location:  Convention Center, Halls G-J, Poster Section 26

About PRS-343

PRS-343 is a bivalent, bispecific fusion protein targeting CD137 (4-1BB) and HER2 comprising an agonistic CD137-targeting Anticalin genetically linked to a HER2-targeting antibody. CD137 is a key costimulatory immunoreceptor and a member of the TNF-receptor (TNFR) superfamily. While multiple lines of evidence show that CD137 is a highly promising therapeutic target in cancer, current mAb approaches are not designed to achieve a tumor-mediated activation and, therefore, may display toxicity and a limited therapeutic window due to peripheral T cell and NK cell activation. To overcome this limitation, we generated PRS-343, which is designed to promote CD137 clustering by bridging CD137-positive T cells with HER2-positive tumor cells, thereby providing a potent costimulatory signal to tumor antigen-specific T cells.

About Pieris Pharmaceuticals: Pieris is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin ® , Anticalins ® are registered trademarks of Pieris. For more information visit  www.pieris.com .

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; our liquidity and ability to fund our future operations; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov , including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and the Company's Quarterly Reports on Form 10-Q.

Company Contact:   Pieris Pharmaceuticals, Inc.  Darlene Deptula-Hicks  SVP & Chief Financial Officer  +1-603-553-5803  deptula@pieris.com Investor Relations Contact:   The Trout Group Thomas Hoffmann +1-646-378-2931 thoffmann@troutgroup.com Media Inquiries:    Gretchen Schweitzer  +49 172 861 8540  gschweitzer@macbiocom.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 0

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 96

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 37

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 304

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 89

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 85

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices

Updated Category News Views 22

Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 13

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 56

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading

Top 5 Most Recently Viewed Articles

SK Chemicals Delivers Sustainable Innovation at ECS 2025

Updated Category News Views 484

SK Chemicals at the European Coatings Show 2025 SK chemicals has proudly participated in the European Coatings Show (ECS) 2025, marking a significant moment for the company as it engages in marketing its innovative materials. This event is known for attracting key players in the coatings and paint sector, and this year was no exception, with over 1,000 exhibitors and more...

Continue Reading
Analyzing TJX Companies' Increased Short Interest Trends

Updated Category News Views 230

Understanding the Rise in TJX Companies' Short Interest The short interest for TJX Companies (NYSE: TJX) has seen a significant uptick, now standing at 14.55 million shares sold short, which constitutes 1.29% of its float. This marks a 21.7% increase since the prior reporting period. Given the current trading volume, traders would require approximately 2.49 days to cover...

Continue Reading
IGT Expands Collaboration with La Française des Jeux for Instant Tickets

Updated Category News Views 69

IGT Expands Collaboration with La Française des Jeux Company to deliver top-performing instant ticket games to one of the world's largest lotteries International Game Technology PLC (NYSE: IGT) has officially entered a three-year partnership with La Française des Jeux (FDJ), the esteemed operator of the French National Lottery. This significant agreement follows a...

Continue Reading
Archer Expands Footprint with New Manufacturing Facility Opening

Updated Category News Views 267

Archer Expands Footprint with New Manufacturing Facility Opening New state-of-the-art facility doubles manufacturing capacity and adds more than 200 local jobs Archer, one of the fastest-growing meat snack brands in the U.S., is celebrating a significant milestone with the grand opening of its new manufacturing facility. This latest addition in Vernon, California,...

Continue Reading
Bumble Faces Downgrade from KeyBanc Amid Revenue Concerns

Updated Category News Views 309

Bumble Inc (NASDAQ: BMBL) took a hit when KeyBanc downgraded its rating from 'Overweight' to 'Sector Weight', shaking the confidence of many investors. The downgrade was more than just a simple reassessment; it became a catalyst for a stock value decline in premarket trading that had traders watching their screens with bated breath. KeyBanc Downgrade: A Harbinger of...

Continue Reading